• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Raised Revenue Outlook Could Be A Game Changer For Aurinia Pharmaceuticals (AUPH)

    Simply Wall St·11/02/2026 03:41:39
    Listen to the news
    • Aurinia Pharmaceuticals reported third quarter 2026 revenue of US$83.7 million and net income of US$31.7 million, with basic EPS from continuing operations at US$0.24, broadly in line with the prior year period.
    • For the first nine months of 2026, Aurinia Pharmaceuticals recorded US$244.62 million in revenue and US$103.47 million in net income, while also lifting full year revenue guidance to a range of US$325 million to US$330 million.
    • Now the focus turns to how this raised full year revenue guidance could influence Aurinia Pharmaceuticals' broader investment narrative and risk profile.

    Scan how Aurinia Pharmaceuticals' raised revenue guidance compares with peers and spot other companies recalibrating expectations in our curated list of 33 high quality undervalued stocks.

    Aurinia Pharmaceuticals Investment Narrative Recap

    Aurinia Pharmaceuticals is still largely a LUPKYNIS story, so owning the stock means believing that demand for this lupus nephritis therapy can support the current business while the autoimmune pipeline matures. The latest quarter showed revenue and earnings levels that kept basic EPS from continuing operations flat year on year, which points to a relatively steady near term base.

    The raised full year revenue guidance nudges the near term narrative toward firmer commercial execution rather than a step change. For now, the key upside catalyst remains further LUPKYNIS market penetration and label or access expansions, while concentration in a single product and ongoing drug pricing and reimbursement pressures sit as the biggest operational risks.

    The most relevant update here is the higher 2026 revenue guidance range of US$325 million to US$330 million, up from US$315 million to US$325 million. This sits alongside nine month revenue of US$244.62 million and net income of US$103.47 million, which provides a clearer sense of how management views the rest of the year from an operational perspective.

    This guidance revision feeds directly into the main catalyst investors watch, which is the durability and breadth of LUPKYNIS demand while aritinercept and other assets remain in development. It also highlights execution risk. Any future shift in this outlook, whether from competition, pricing pressure or slower uptake, would likely be more significant to the thesis than the single quarter earnings line.

    Aurinia Pharmaceuticals' current analyst narrative points to forecast revenue of US$453.5 million and projected earnings of US$169.9 million by 2029. These figures are based on an assumed 13.3% yearly revenue growth rate and a decline in earnings of about US$144.2 million from US$314.1 million today.

    Uncover how Aurinia Pharmaceuticals' fair value indicates a 9% potential upside to its current price before the market closes that gap.

    NasdaqGM:AUPH 1-Year Stock Price Chart
    NasdaqGM:AUPH 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate lens on Aurinia Pharmaceuticals leans heavily on the risk that LUPKYNIS remains the only meaningful profit engine. The most bearish analysts were working off revenue of about US$429.9 million and earnings of roughly US$60.8 million by 2029, far below consensus. Those estimates predate this new guidance, so opinions are likely to evolve. It is worth exploring several viewpoints before deciding what makes sense for you.

    Explore 3 other Aurinia Pharmaceuticals fair value estimates, including one that suggests it could be worth just $18.00.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment performance rarely comes from following the herd, so trust your own research and judgment.

    Looking For More Investment Ideas Beyond Aurinia Pharmaceuticals?

    If the Aurinia Pharmaceuticals story has sharpened your thinking but you want a broader watchlist, the Simply Wall St Screener can help you quickly surface other opportunities that fit your preferences and risk tolerance.